Industry News (Breast Cancer)

IND Submitted for SERM Product

Published in Women's Health Weekly, March 15th, 1999

Ligand Pharmaceuticals Inc., San Diego, California, announced that Wyeth-Ayerst Laboratories, the pharmaceutical division of American Home Products, has submitted an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for the compound ERA-923, a tissue-selective estrogen receptor (ER) modulator for the treatment of breast cancer.

The IND for ERA-923 is the second IND submitted for a compound emanating from the Ligand/Wyeth-Ayerst collaboration. On March 26, 1998, Wyeth-Ayerst submitted an IND for the tissue selective estrogen (TSE), TSE-424, for the treatment of post-menopausal osteoporosis.

"Recent clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (1999-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry